CA3256035A1 - COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS - Google Patents
COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONSInfo
- Publication number
- CA3256035A1 CA3256035A1 CA3256035A CA3256035A CA3256035A1 CA 3256035 A1 CA3256035 A1 CA 3256035A1 CA 3256035 A CA3256035 A CA 3256035A CA 3256035 A CA3256035 A CA 3256035A CA 3256035 A1 CA3256035 A1 CA 3256035A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- protein
- target
- seq
- mucoadhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263331216P | 2022-04-14 | 2022-04-14 | |
| US63/331,216 | 2022-04-14 | ||
| US202263418570P | 2022-10-23 | 2022-10-23 | |
| US63/418,570 | 2022-10-23 | ||
| PCT/US2023/065732 WO2023201304A2 (en) | 2022-04-14 | 2023-04-13 | Compositions for preventing or treating coronavirus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3256035A1 true CA3256035A1 (en) | 2023-10-19 |
Family
ID=88330386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3256035A Pending CA3256035A1 (en) | 2022-04-14 | 2023-04-13 | COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12460193B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4507729A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025512512A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3256035A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023201304A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024209218A1 (en) * | 2023-04-05 | 2024-10-10 | Diosynvax Ltd | Coronavirus vaccines inducing broad immunity against variants |
| CN117777309B (zh) * | 2023-11-28 | 2024-10-18 | 北京吉诺卫生物科技有限公司 | 一种包括xbbbq11类抗体的融合蛋白构建体、制备方法及其在疫苗中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US20030224000A1 (en) | 2001-12-21 | 2003-12-04 | Kokai-Kun John Fitzgerald | Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| AU2007281433A1 (en) | 2006-08-04 | 2008-02-07 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
| WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| SI2766397T1 (sl) | 2011-10-11 | 2018-09-28 | F. Hoffmann-La Roche Ag | Izboljšano sestavljanje bispecifičnih protiteles |
| JP7332157B2 (ja) | 2017-01-24 | 2023-08-23 | ノースウェスタン ユニバーシティ | アンジオテンシン変換酵素2(ace2)の活性な低分子量変異体 |
| US20200095327A1 (en) | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| US20250263466A1 (en) | 2020-02-03 | 2025-08-21 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| KR20220140568A (ko) | 2020-02-11 | 2022-10-18 | 벤더르빌트 유니버시티 | 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체 |
| PH12022552164A1 (en) | 2020-02-19 | 2023-11-29 | United Biomedical Inc | Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19) |
| HUE062777T2 (hu) | 2020-02-26 | 2023-12-28 | Vir Biotechnology Inc | SARS-CoV-2 elleni antitestek |
| JP2023517234A (ja) | 2020-03-09 | 2023-04-24 | アブセレラ バイオロジクス インコーポレイテッド | 抗コロナウイルス抗体および使用の方法 |
| US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
| CN111303280B (zh) | 2020-03-22 | 2022-01-07 | 中国人民解放军军事科学院军事医学研究院 | 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用 |
| EP4127174A4 (en) * | 2020-03-23 | 2024-05-01 | Monash University | ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASES |
| WO2021195418A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| WO2021195326A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| US20230122364A1 (en) | 2020-03-27 | 2023-04-20 | Vanderbilt University | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) |
| CR20220552A (es) | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| WO2021216547A1 (en) | 2020-04-20 | 2021-10-28 | Sorrento Therapeutics, Inc. | Pulmonary administration of ace2 polypeptides |
| TW202212354A (zh) * | 2020-08-03 | 2022-04-01 | 美商健生生物科技公司 | 用於病毒治療劑中之多向生物運輸的材料及方法 |
| WO2022075667A1 (ko) * | 2020-10-05 | 2022-04-14 | 한양대학교 산학협력단 | 안정화된 ace2 변이체, 이를 이용한 ace2-fc 융합단백질 및 covid-19 예방 또는 치료용 약학 조성물 |
| WO2022082217A1 (en) | 2020-10-16 | 2022-04-21 | Eureka Therapeutics, Inc. | Compositions for preventing or treating viral and other microbial infections |
-
2023
- 2023-04-13 CA CA3256035A patent/CA3256035A1/en active Pending
- 2023-04-13 WO PCT/US2023/065732 patent/WO2023201304A2/en not_active Ceased
- 2023-04-13 EP EP23789155.1A patent/EP4507729A2/en active Pending
- 2023-04-13 JP JP2024560783A patent/JP2025512512A/ja active Pending
-
2024
- 2024-10-11 US US18/914,016 patent/US12460193B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12460193B2 (en) | 2025-11-04 |
| JP2025512512A (ja) | 2025-04-17 |
| US20250109390A1 (en) | 2025-04-03 |
| WO2023201304A3 (en) | 2023-11-23 |
| EP4507729A2 (en) | 2025-02-19 |
| WO2023201304A2 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12460193B2 (en) | Compositions for preventing or treating coronavirus infections | |
| US11440952B2 (en) | Compositions for preventing or treating viral and other microbial infections | |
| JP7863512B2 (ja) | Ace2標的化ウイルスに対して有用な結合タンパク質 | |
| US20230257726A1 (en) | Ace2 compositions and methods | |
| JP7554837B2 (ja) | 可溶性ace2及び融合タンパク質、並びにその適用 | |
| US12459988B2 (en) | Chimeric protein comprising an anti-influenza virus antibody moiety and a mucoadhesive peptide fragment for preventing or treating influenza infections | |
| CA3202566A1 (en) | Neutralizing monoclonal antibodies against covid-19 | |
| TW202221024A (zh) | 結合sars-cov-2 s蛋白之中和抗體 | |
| WO2024229151A2 (en) | Multimeric coronavirus binding molecules and uses thereof | |
| US20260000751A1 (en) | Coronavirus vaccines and methods of use thereof | |
| WO2026030503A2 (en) | Compositions and methods for preventing the spread of viruses | |
| JP2024502783A (ja) | コロナウイルスワクチン | |
| RU2837537C1 (ru) | Растворимый апф2, его слитый белок и способы их применения | |
| HK40064110A (en) | Compositions for preventing or treating viral and other microbial infections | |
| Geng | Receptor recognition of SARS-CoV-2 and vaccine design | |
| JP2026514211A (ja) | 新型コロナウイルス感染予防用経鼻スプレー及びその製造と使用 | |
| HK40083738A (en) | Soluble ace2 and fusion protein, and applications thereof | |
| KR20220041561A (ko) | 스캐폴드 기반의 융합 단백질을 포함하는 바이러스 감염병 예방 또는 치료용 항원 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241011 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250218 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250221 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250225 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250225 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250305 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250305 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250327 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250401 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260525 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260528 |